Novo Nordisk Transfers Parkinson's Therapy to AI Startup Supported by Mark Zuckerberg

Novo Nordisk has transferred rights to an experimental Parkinson's disease therapy to the AI startup Cellular Intelligence, which is backed by Mark Zuckerberg. This partnership aims to accelerate the therapy's development through clinical trials, with Novo potentially earning milestone payments and royalties upon success.